Shanghai Fosun Pharmaceutical (02196): The registration application for Fosun Pharmaceutical Capsules containing citric acid has been accepted.

Shanghai Fosun Pharmaceutical (02196) announced that its holding subsidiary, Jinzhou Aohong Pharmaceutical Co., Ltd., has recently had its drug registration application for the citrate fulvestrant capsules (project code: FCN-437c, registration category: chemical drug 1; hereinafter referred to as "the new drug") accepted by the National Medical Products Administration (hereinafter referred to as "NMPA"). The indication for this application is for the treatment of locally advanced or metastatic breast cancer with hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative, to be used in combination with aromatase inhibitors as initial endocrine therapy for premenopausal, postmenopausal, and perimenopausal female breast cancer patients.